PRDM9 and posterior cortical atrophy: Due to its extensive pathogenic function, the histone methyltransferase EZH2 is an obvious therapeutic target, especially for advanced PCa, e.g. castration-resistant adenocarcinomas (CRPC) and malignancies with neuroendocrine features (NEPC) [54].